MedTrace Logo

Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria

NCT05362539 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 246

Last updated 2022-05-05

No results posted yet for this study

Summary

The current study aimed to assess the diagnostic performance of novel urine-based DNA hypermethylation of six genes (GATA4, P16, P14, APC, CDH1 and CD99) for UBC detection in patients with hematuria.

Conditions

Interventions

PROCEDURE

Cystoscopy

diagnostic cystoscopy for detection of any bladder lesions

DIAGNOSTIC_TEST

Computed tomography

Computed tomography for patients to exclude bladder lesions

GENETIC

DNA hypermethylation assay

DNA hypermethylation assay of six genes (GATA4, P16, P14, APC, CDH1 and CD99)

DIAGNOSTIC_TEST

Urine cytology

voided urine cytology for all patients

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Amr A Elsawy · Mansoura University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2021-06-01
Completion
2022-04-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05362539 on ClinicalTrials.gov